



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: 15270J-004765US

DALE B. SCHENK et al.

Appln. No.: 09/724,288

Group Art Unit: 1649

Confirmation No.: 9431

Examiner: Sharon L. Turner

Filed: November 28, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97 and §1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited on April 5, 2006 with the United States Postal Service in an envelope as "Express Mail Post Office To Addressee," mailing label No. EV 843 555 534 US addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

4/5/06
Date

Monica Moreno
Monica Moreno

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of references 585-618, and 620-641 can be found in Application No. 09/322,289, filed May 28, 1999 (Attorney Docket No. 15270J-004740US). Copies of references 648-655, 662-666, 676-678, 681-682, 687-690, 694-701, 727-729, and 731-738 are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98; issued as U.S. 6,787,523 on 09/07/04;

09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00; issued as U.S. 6,787,143 on 09/07/04;
09/723,927 filed 11/28/00; issued as U.S. 6,787,138 on 09/07/04;
09/723,762 filed 11/28/00; issued as U.S. 6,787,144 on 09/07/04 ;
09/724,102 filed 11/28/00; issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00; issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04; issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04; issued as U.S. 6,818,218 on 11/16/04;
10/815,391 filed 03/31/04; issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
11/108,102 filed 04/15/05;
11/245,524 filed 10/07/05;
10/934,609 filed 09/02/04; issued as U.S. 6,946,135 on 09/20/2005;
11/245,916 filed 10/7/05;
10/933,559 filed 09/02/04; issued as U.S. 6,972,127 on 12/06/05;
10/934,819 filed 09/02/04;
10/815,353 filed 03/31/04; issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04; issue fee paid 01/24/05;
10/815,404 filed 03/31/04; issued as U.S. 6,982,084 on 01/03/06;
10/884,892 filed 07/01/04; issued as U.S. 6,962,707 on 11/08/05;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00; issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;

10/923,471 filed 08/20/04;
10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04;
10/923,605 filed 08/20/04;
10/923,267 filed 08/20/04;
10/923,469 filed 08/20/04;
09/724,940 filed 11/28/00; issued as U.S. 6,905,686 on 06/14/05;
09/724,961 filed 11/28/00; issued as U.S. 6,743,427 on 6/1/04;
10/823,463 filed 04/12/04;
11/058,757 filed 02/14/05;
09/580,018 filed 05/26/00; issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00; issued as U.S. 6,750,324 on 6/15/04;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00; issued as U.S. 6,787,637 on 09/07/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,024 filed 04/12/04;
10/889,999 filed 04/12/04;
10/890,000 filed 07/12/04;
10/890,070 filed 07/12/04;
10/890,071 filed 07/12/04;
09/723,765 filed 11/28/00;
10/822,968 filed 04/12/04;
09/724,567 filed 11/28/00; issued as U.S. 6,890,535 on 05/10/05;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00; issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00; issued as U.S. 6,936,246 on 08/30/05;
09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810 filed
05/26/00); and,

Application No. 09/724,288
Supplemental Information Disclosure Statement filed April 5, 2006

09/979,952 filed 04/09/02 (U.S. National Stage of PCT/US00/15239 filed 06/01/00); issued as U.S. 6,913,745 on 07/05/05.

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;

10/789,273 filed 2/27/04;

10/232,030 filed 08/30/02;

10/010,942 filed 12/6/01;

10/388,389 filed 03/12/03;

10/703,713 filed 11/07/03;

10/704,070 filed 11/07/03;

10/388,214 filed 03/12/03;

10/858,855 filed 06/01/04;

10/771,174 filed 02/04/04;

11/260,047 filed 10/26/05;

11/304,986 filed 12/15/05;

11/305,889 filed 12/15/05;

60/637,253 filed 12/16/04;

11/305,899 filed 12/15/05;

60,637,138 filed 12/16/04;

11/303,478 filed 12/15/05;

11/304,072 filed 12/15/05;

60/736,119 filed 11/10/05;

60/691,821 filed 06/17/05;

60/735,687 filed 11/10/05;

10/544,093 filed 08/01/05 (U.S. National Stage of PCT/US04/02856 filed 01/31/04);

_____ filed 11/10/05;

_____ filed 11/10/05; and

_____ filed 01/27/06.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;

60/080,970 filed 04/07/98;

09/580,015 filed 05/26/00;

09/580,019 filed 05/26/00;

09/724,291 filed 11/28/00;

09/585,656 filed 06/01/00;

09/723,766 filed 11/27/00;

09/723,725 filed 11/27/00;

09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302 filed 06/01/00);

09/579,690 filed 05/26/00;

60/067,219 filed 12/03/97;

60/079,697 filed 03/27/98;

09/204,838 filed 12/03/98;

09/724,921 filed 11/28/00;

09/724,929 filed 11/28/00;

60/137,010 filed 06/01/99;

60/251,892 filed 12/06/00;

60/137,047 filed 06/01/99;

60/136,655 filed 05/28/99, and

09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;

60/444,150 filed 02/01/03;

60/622,525 filed 10/26/04;

60/636,684 filed 12/15/04;
60/636,842 filed 12/15/04;
60/636,810 filed 12/15/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04;
60/648,631 filed 01/28/05;
60/474,654 filed 05/30/03;
60/530,481 filed 12/17/03; and
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she is invited to call the undersigned who will be happy to supply them.


As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the

Application No. 09/724,288
Supplemental Information Disclosure Statement filed April 5, 2006

undersigned's Deposit Account No. 19-4880. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Registration No. 42,397

SUGHRUE MION, PLLC
Telephone: (650) 625-8100
Facsimile: (650) 625-8110

MOUNTAIN VIEW OFFICE

23493

CUSTOMER NUMBER

Date: April 5, 2006
37303_1



PTO/SB/08A (08-03)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 9

Complete if Known

Application Number	09/724,288
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004765US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	686	6,972,127	12-06-2005	Schenk	
	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	693	2005/0191314 A1	09-01-2005	Schenk	
	713	6,936,698	08-30-2005	Taylor	
	716	6,933,368	08-23-2005	Co et al.	
	685	2005/0163788 A1	07-28-2005	Schenk	
	657	6,913,745	07-05-2005	Schenk	
	715	2005/0136054 A1	06-23-2005	Adair et al.	
	658	6,905,686	06-14-2005	Schenk	
	714	2005/0123534 A1	06-09-2005	Adair et al.	
	659	6,890,535	05-10-2005	Schenk	
	683	2005/0059802 A1	03-17-2005	Schenk et al.	
	684	2005/0059591 A1	03-17-2005	Schenk et al.	
	661	2005/0009150 A1	01-13-2005	Basi et al.	
	583	2004/0265919 A1	12-30-2004	Vanderstichlele et al.	
	581	2004/0247612 A1	12-09-2004	Wang	
	582	2004/0241164 A1	12-02-2004	Bales et al.	
	673	6,808,712	10-26-2004	Schenk	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	708	2003/0039645 A1	10-14-2003	Adair et al.	
	675	6,710,226	02-23-2004	Schenk	
	712	6,639,055	10-28-2003	Carter et al.	
	709	6,632,927	10-14-2003	Adair et al.	
	730	2003/0166557 A1	09-04-2003	Minna et al.	
	702	6,548,640	04-15-2003	Winter	
	725	6,538,124	03-25-2003	Idusogie et al.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

37305_1




INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/724,288	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Sharon L. Turner	
Sheet	2	of	9	Attorney Docket Number	15270J-004765US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	726	6,528,624	03-04-2003	Idusogie et al.	
	710	6,407,213	06-18-2002	Carter et al.	
	720	6,277,375	08-21-2001	Ward	
	724	6,194,551	02-27-2001	Idusogie et al.	
	704	6,180,370	01-30-2001	Queen et al.	
	719	6,165,745	12-26-2000	Ward et al.	
	723	6,121,022	09-19-2000	Presta et al.	
	711	6,054,297	04-25-2000	Carter et al.	
	722	5,869,046	02-09-1999	Presta et al.	
	707	5,859,205	01-12-1999	Adair et al.	
	642	5,702,906	12-30-1997	Rosenthal	
	643	5,693,762	12-02-1997	Queen et al.	
	705	5,693,761	12-02-1997	Queen et al.	
	721	5,677,425	10-14-1997	Bodmer et al.	
	717	5,648,260	07-15-1997	Winter et al.	
	718	5,624,821	04-29-1997	Winter et al.	
	644	5,618,920	04-08-1997	Robinson et al.	
	584	5,589,154	12-31-1996	Anderson	
	706	5,585,089	12-17-1996	Queen et al.	
	619	5,530,101	06-25-1996	Queen et al.	
	645	5,258,498	11-02-1993	Huston et al.	
	703	5,225,539	07-06-1993	Winter	
	646	4,816,567	03-28-1989	Cabilly et al.	
	647	4,816,397	03-28-1989	Boss et al.	
	691	11/245,524	filed 10-07-2005	Schenk	
	692	11/245,916	filed 10-07-2005	Schenk	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
Application Number			09/724,288	
Filing Date			November 28, 2000	
First Named Inventor			Schenk, Dale B.	
Art Unit			1649	
Examiner Name			Sharon L. Turner	
Attorney Docket Number			15270J-004765US	
Sheet	3	of	9	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	633	WO	96/08665	A2	03-21-1996			
	630	WO	95/17085	A1	06-29-1995			
	696	WO	95/06407	A1	03-09-1995			
	736	WO	94/10569	A1	05-11-1994			
	648	WO	91/09967	A1	07-11-1991			
	738	EP	626 390	A1	11-30-1994			
	737	EP	620 276	A1	10-19-1994			
	632	JP	07-132033	A	05-23-1995			abs t. onl y
	631	JP	62-267297	A	11-19-1987			abs t. onl y
	701	WO	05/014041	A2	02-17-2005			
	585	WO	04/080419	A2	09-23-2004			
	586	WO	03/077858	A2, A3	09-25-2003			

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Sharon L. Turner
Sheet	4	of	9	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (1986).	
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <i>Neuroscience Letters</i> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <i>The Scientist</i> , 18(20):28-29 (2004).	
	677	ANKARCRONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <i>Int. J. Geriatric Psychiatry</i> , 20:101-105 (2005).	
	681	AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies," <i>Progress in Neurobiol.</i> , 68:209-245 (2002).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy," <i>J. Neurosci.</i> , 22(18):7873-7878 (2002).	
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561	
	591	CHROMY et al., "Self-assembly of Aβ(1-42) into globular neurotoxins," <i>Biochemistry</i> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid-β protein are generated from the β-amyloid precursor protein by different protease activities," <i>PNAS</i> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <i>Nat. Neurosci.</i> , 5:1055-1057 (2002).	
	699	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <i>J. Neurosci. Res.</i> , 58:120-129 (1999).	
	687	COX et al., "Adjuvants---a classification and review of their modes of action," <i>Vaccine</i> , 15(3):248-256 (1997).	
	689	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <i>Rev. In Neurosciences</i> , 5:213-225 (1994).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Sharon L. Turner
Sheet	5	of	9	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	594	DEMATTO et al., "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <u>Science</u> , 295(5563):2264-2267 (2002).	
	698	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.	
	735	DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <u>J. Molecular Recognition</u> , 4(2-3):85-91 (1991).	
	595	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002).	
	596	DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003).	
	597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).	
	598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).	
	599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).	
	600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).	
	650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992).	
	601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).	
	602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).	
	603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Substitute for form 1449B/PTO	
				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
Examiner Name	Sharon L. Turner				
Attorney Docket Number	15270J-004765US				
Sheet	6	of	9		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	634	Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01.	
	635	Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93.	
	636	Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93.	
	637	Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99.	
	604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).	
	605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).	
	694	GUPTA et al., "Adjuvants for human vaccines---current status, problems, and future prospects," <u>Vaccine</u> , 13(14):1263-1275 (1995).	
	606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).	
	664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1998).	
	607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <u>Nat. Med.</u> , 8(11):1270-1275 (2002).	
	662	IDA et al., "Analysis of Heterogeneous β A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <u>J. Biol. Chem.</u> , 271(37):22908-22914 (1996).	
	608	IRIZARRY et al., "Alzheimer disease therapeutics," <u>J. Neuropathol. Exp. Neurol.</u> , 60(10):923-928 (2001).	
	609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <u>Physiol. Behav.</u> , 73(5):873-886 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Sharon L. Turner
Sheet	7	of	9	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <u>J. Neurosci. Res.</u> , 46:336-348 (1996).	
	729	KASCSAK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <u>J. Virology</u> , 61(12):3688-3693 (1987).	
	628	KOFLER et al., "Mechanism of Allergic Cross-Reactions--III. cDNA Cloning and Variable-Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <u>Mol. Immunology</u> , 29(2):161-166 (1992).	
	627	KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies ^{1,2} ," <u>J. Immunol.</u> , 157(6):2430-2439 (1996).	
	695	KUO et al., "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <u>J. Biol. Chem.</u> , 271(8):4077-4081 (1996).	
	734	KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <u>Appl. Pathol.</u> , 3(1-2):39-54 (1985).	
	651	LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <u>J. Immunology</u> , 166(3):1748-1754 (2001).	
	727	LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <u>J. Histochemistry and Cytochemistry</u> , 32(3):322-328 (1982).	
	665	LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <u>Protein Engineering</u> , 11(6):495-500 (1998).	
	666	MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <u>Curr. Opin. Mol. Ther.</u> , 6(5):482-490 (2004).	
	731	MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <u>Clin. Exp. Immunol.</u> , 50(2):390-396 (1982).	
	610	MATTSON et al., "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.




Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Sharon L. Turner
				Attorney Docket Number	15270J-004765US
Sheet	8	of	9		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	732	MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <u>Laboratory Investigation</u> , 64(3):400-404 (1991).	
	611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002).	
	612	MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003).	
	613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003).	
	652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <u>PNAS</u> , 86:3833-3837 (1989).	
	614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).	
	615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <u>Biochemistry</u> , 38(12):3570-3578 (1999).	
	654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <u>PNAS</u> , 85:3080-3084 (1998).	
	682	PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <u>Drugs</u> , 53(5):752-768 (1997).	
	653	PAUL, W. E., eds., <i>Fundamental Immunology</i> , Third Edition, pages 292-295, Raven Press, New York (1993).	
	616	PFEIFER et al., "Cerebral hemorrhage after passive anti-A β immunotherapy," <u>Science</u> , 298(5597):1379 (2002).	
	733	PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <u>Hybridoma</u> , 15(5):379-386 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Sharon L. Turner
Sheet	9	of	9	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <u>J. Neurosci.</u> , 25(3):629-636 (2005).	
	638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.	
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	
	655	RUDIHOFF et al., "Single amino acid substitution altering antigen-binding specificity," <u>PNAS</u> , 79:1979-1983 (1982).	
	617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002).	
	629	SEIDL et al., "Predominant V _H genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <u>PNAS</u> , 96:2262-2267 (1999).	
	618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5594):789-791 (2002).	
	622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003).	
	697	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).	
	620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).	
	621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).	
	678	SOUDER et al., "Overview of Alzheimer's disease," <u>Nurs. Clin. N. Am.</u> , 39:545-559 (2004).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Sharon L. Turner
Sheet	10	of	9	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	700	VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family," <u>Kidney International</u> , 61:907-912 (2002).	
	690	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease," <u>Drugs Aging</u> , 19(7):487-494 (2002).	
	623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002).	
	624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	
	676	<i>Webster's New World Dictionary</i> , page 1387, therapeutic (1988).	
	688	<i>Webster's New World Dictionary of American English</i> , Third College Edition, page 1078 (1988).	
	625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003).	
	728	YAMADA et al., "Generation and Characterization of Rat Monoclonal Antibodies Against Human Serum Amyloid A," <u>Scand. J. Immunol.</u> , 46(2):175-179 (1997).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.